AMENDMENTS TO CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application.

1-21. (Cancelled)

- 22. (Withdrawn) Nucleic acid coding for human semaphorin 6A-1 comprising:
 - (a) the nucleotide sequence shown in SEQ ID NO:1,
 - (b) a sequence corresponding to the nucleotide sequence shown in SEQ ID NO: 1 within the degeneration of the genetic code, or
 - (c) a sequence which hybridizes with the sequences of (a) or/and(b) under stringent conditions with the proviso that it contains a nucleic acid coding for a binding domain of human
 - (d) the nucleotide sequence shown in SEQ ID NO:3,

semaphorin 6A-1 comprising:

- (e) a sequence corresponding to the nucleotide sequence shown in SEQ ID NO:3 within the degeneration of the genetic code, or
- (f) a sequence which hybridizes with the sequences of (d)or/and (e) under stringent conditions.
- 23. (Withdrawn) A nucleic acid encoding for human semaphorin 6A-1 as recited in Claim 22, wherein the nucleic acid sequence has a sequence homology to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3 of greater than about 80%.
- 24. (Withdrawn) A nucleic acid comprising a sequence which hybridizes under stringent conditions to the nucleic acid sequence of Claim 23.

- 25. (Withdrawn) A nucleic acid comprising a nucleic acid which encodes a protein having a semaphorin domain and hybridizes under stringent conditions to sequence SEQ ID NO:1 or SEQ ID NO:3 of Claim 22.
- 26. (Currently amended) A An isolated protein comprising a protein encoded by SEQ ID NO:1.

27-28. (Cancelled)

- 29. (Currently amended) A An isolated protein comprising a protein encoded by the SEQ ID NO:3.
- 30-31. (Cancelled)
- 32. (Currently amended) A An isolated protein comprising the amino acid sequence of SEQ ID NO:2.
- 33. (Currently amended) A An isolated protein comprising the amino acid sequence of SEQ ID NO:4.
- 34. (Currently amended) A An isolated protein comprising a protein encoded by the nucleic acid sequences of Claim 22 coding for human semaphorin 6A-1 comprising:
 - (a) the nucleotide sequence shown in SEQ ID NO:1.
 - (b) a sequence corresponding to the nucleotide sequence shown in SEQ ID NO: 1 within the degeneration of the genetic code, or
 - (c) a sequence which hybridizes with the sequences of (a) or/and (b) under stringent conditions with the proviso that it contains a nucleic acid coding for a binding domain of human semaphorin 6A-1 comprising:

- (d) the nucleotide sequence shown in SEQ ID NO:3,

 (e) a sequence corresponding to the nucleotide sequence shown in SEQ ID NO:3 within the degeneration of the genetic code, or

 (f) a sequence which hybridizes with the sequences of (d) or (e), or both, under stringent conditions.
- 35. (Withdrawn) An antibody that binds to the protein of Claim 32.
- 36. (Withdrawn) An antibody that binds to the protein of Claim 33.
- 37. (Withdrawn) An antibody that binds to the protein of Claim 34.
- 38. (Previously presented) A composition comprising the protein of Claim 32 and a pharmaceutically acceptable carrier.
- 39. (Previously presented) A composition comprising the protein of Claim 33 and a pharmaceutically acceptable carrier.
- 40. (Previously presented) A composition comprising the protein of Claim 34 and a pharmaceutically acceptable carrier.
- 41. (Withdrawn) A composition comprising the nucleic acid of Claim 22 and a pharmaceutically acceptable carrier.
- 42. (Withdrawn) A composition comprising the nucleic acid of Claim 23 and a pharmaceutically acceptable carrier.

- 43. (Withdrawn) A composition comprising the nucleic acid of Claim 24 and a pharmaceutically acceptable carrier.
- 44. (Withdrawn) A recombinant vector comprising at least one copy of a nucleic acid sequence according to Claim 22.
- 45. (Withdrawn) A recombinant vector comprising at least one copy of a nucleic acid sequence according to Claim 23.
- 46. (Withdrawn) A recombinant vector according to Claim 44 wherein the vector is a eukaryotic vector.
- 47. (Withdrawn) A recombinant vector according to Claim 45, wherein the vector is a eukaryotic vector.
- 48. (Withdrawn) A cell transformed with the recombinant vector of Claim 44.
- 49 (Withdrawn) A cell transformed with the recombinant vector of Claim 45.
- 50. (Withdrawn) A method comprising administration of the protein of Claim 26 to an animal or a human in an amount effective to modulate differentiation, apoptosis, cytoskeletal stabilization, plasticity or neurite growth.
- 51. (Withdrawn) A method comprising administration of the protein of Claim 29 to an animal or a human in an amount effective to modulate differentiation, apoptosis, cytoskeletal stabilization, plasticity or neurite growth.

- 52. (Withdrawn) A method comprising administration of the protein of Claim 34 to an animal or a human in an amount effective to modulate differentiation, apoptosis, cytoskeletal stabilization, plasticity or neurite growth.
- 53. (Withdrawn) A method comprising administration of the nucleic acid of Claim 22 to an animal or a human in an amount effective to modulate differentiation, apoptosis, cytoskeletal stabilization, plasticity or neurite growth.
- 54. (Withdrawn) A method comprising administration of the nucleic acid of Claim 23 to an animal or a human in an amount effective to modulate differentiation, apoptosis, cytoskeletal stabilization, plasticity or neurite growth.
- 55. (Withdrawn) A method comprising administration of the nucleic acid of Claim 24 to an animal or a human in an amount effective to modulate differentiation, apoptosis, cytoskeletal stabilization, plasticity or neurite growth.
- 56. (Withdrawn) A method comprising administration of the nucleic acid of Claim 25 to an animal or a human in an amount effective to modulate differentiation, apoptosis, cytoskeletal stabilization, plasticity or neurite growth.